Obesity due to excess calories Obesity
Conditions
Interventions
This is a three-arm, parallel, double-blind, placebo-controlled randomized clinical trial. Placebo group: one hundred patients with a Body Mass Index greater than or equal to twenty-five kilograms per
Sponsors
Fundação do abc
Faculdade de Medicina do ABC - Centro Universitário Saúde ABC
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Pacientes com Índice de Massa Corporal (IMC) = 25 kg/m² a 39,9 kg/m²; age between 18 and 60 years; both sexes; glucose level at a maximum of 125 milligrams per deciliter
Exclusion criteria
Exclusion criteria: Patients with neoplasms; recent infections; chronic liver disease; diagnosed depression under treatment; chronic kidney disease; previous bariatric surgery; lung diseases including chronic obstructive pulmonary disease; recent cardiac event within the last six months; rheumatological diseases and other autoimmune diseases; excessive alcohol consumption; dementia; obesity associated with genetic syndromes; decompensated hypothyroidism; menopausal women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected to observe the efficacy of white adipose tissue activator peptide cyclophilin A (WATACAP) in reducing body weight and decreasing body fat percentage by body composition, verified through anthropometric assessments, at the end of the 180-day intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| An improvement in the behavior of the inflammatory markers Interleukin 6 (IL6), Tumor Necrosis Factor alpha (TNF alpha), and high-sensitivity C-reactive protein (hs-CRP), verified through laboratory tests, is expected to be observed over the 180 days of the intervention | — |
Countries
BR
Contacts
Public ContactDavi Vantini
Centro Universitário FMABC
Outcome results
None listed